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Granulomatosis with polyangiitis (Wegener’s granulomatosis) 
with hard palate and bronchial perforations treated with rituximab 
— a case report
Opis przypadku pacjenta z perforacją podniebienia twardego i oskrzeli w przebiegu 
ziarniniakowatości z zapaleniem naczyń (ziarniniaka Wegenera) leczonego rituximabem
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Abstract
We present a case of a 57-year-old woman suffering from granulomatosis with polyangiitis (GPA), who in the seventh months 
of immunosuppressive treatment (cyclophosphamide) progressed with new pulmonary changes and perforations of the hard 
palate and bronchi. Rituximab was introduced resulting in B-cell depletion and disappearance of anti-PR3 antibody. Palatal holes 
have substantially diminished and all bronchial perforations disappeared, covered by fibrous tissue. In the fourth month after 
rituximab administration, large scarring obstruction of the right main bronchus with upper and middle lobes atelectasis emerged. 
Because of increasing dyspnoea, stenotic bronchus was re-opened by bronchoscopy. Intervention was complicated by bilateral 
pneumothorax and later, on the seventh day, by fatal pulmonary bleeding. To our knowledge, this is the first report of GPA refrac-
tory to cyclophosphamide complicated by palatal and bronchial perforations.
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Streszczenie
Przedstawiamy przypadek 57-letniej pacjentki z ziarniniakowatością z zapaleniem naczyń (GPA), u której pomimo trwającej siedem 
miesięcy terapii immunosupresyjnej (cyklofosfamidem) doszło do progresji choroby podstawowej. Z uwagi na to, że u chorej stwier-
dzono nowe zmiany w płucach oraz perforacje oskrzeli i podniebienia twardego, włączono rituximab, co doprowadziło do zmniej-
szenia ilości limfocytów B we krwi obwodowej oraz do zaniknięcia przeciwciał anty-PR3. Perforacje podniebienia uległy znacznemu 
zmniejszeniu, natomiast perforacje oskrzeli zanikły i zostały pokryte przez tkankę włóknistą. Po czterech miesiącach od rozpoczęcia 
leczenia rituximabem uwidoczniono niedodmę płatów górnego i środkowego prawego wynikającą z niedrożności oskrzela głównego 
prawego (wtórnie do procesu bliznowacenia). Z uwagi na narastającą niewydolność oddechową wykonano zabieg poszerzenia 
oskrzela, powikłany obustronną odmą, a następnie, siódmego dnia po zabiegu, doszło do krwawienia dooskrzelowego zakończonego 
zgonem chorej. Według naszej wiedzy przedstawiony przypadek jest pierwszym opublikowanym opisem pacjenta z ziarniniakowa-
tością z zapaleniem naczyń oporną na cyklofosfamid, która została powikłana perforacjami oskrzeli i podniebienia.
Słowa kluczowe: rituximab, ziarniniakowatość z zapaleniem naczyń, zapalenie naczyń, ziarniniak Wegenera, immunosupresja, 
perforacja podniebienia, perforacja oskrzeli 
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Introduction
Granulomatosis with polyangiitis (GPA), 
previously known as Wegener’s granulomatosis, 
is a systemic vasculitis affecting small and me-
dium-size blood vessels involving upper airways, 
lungs, and kidneys [1–4]. The majority of patients 
with GPA show the presence of anti-neutrophil 
cytoplasmic antibodies (ANCA) directed against 
proteinase 3 (anti-PR3) [3, 5]. If GPA is left un-
treated, it usually leads to rapid progression and 
death [5]. Mean survival of untreated patients is 
5 months, with more than 90% of patients dying 
within 2 years of diagnosis [3, 6]. Conventional 
treatment comprises cyclophosphamide combined 
with glucocorticoids, which substantially impro-
ves GPA prognosis [3, 7, 8]. However, some pa-
tients with GPA are refractory to this treatment [8].
Here we present a case of a patient suffering 
from GPA refractory to conventional treatment 
with both hard palate and bronchial perforations, 
who went into remission after rituximab therapy.
Case
We describe a case of a 57-year-old woman 
with a seven-month history of nasal discharge, 
chest pain, polyneuropathy, arthralgia, hearing 
loss, and CT-confirmed pansinusitis. She had 
not taken cocaine in the past, which is one of the 
most common causes of bone and cartilage de-
struction of the nose. Granulomatosis with poly-
angiitis (GPA) was diagnosed based on clinical 
manifestations and the presence of ANCA (with 
a serum titre 1:320, confirmed as anti-PR3 194RU/ 
/mL by ELISA). In addition, bronchial mucosa 
biopsy showed inflammatory granuloma with 
necrosis. She was then aggressively treated with 
monthly i.v. doses (15 mg/kg of body weight) of 
cyclophosphamide and with i.v. methylpredniso-
lone (1 mg/kg), followed by oral prednisone with 
a gradual taper from 40 mg per day, with initial 
clinical improvement. In the seventh month of 
treatment (a total of 6.3 g of cyclophosphamide 
received) progression of the disease was observed, 
manifesting as reappearance of chest pain and 
cough, accompanied by several perforations on 
the hard palate (Fig. 1A). Bronchoscopy revealed 
additional perforations of the trachea at the le-
vel of the carina (Fig. 2A) and bilaterally in the 
lobar bronchi. Treatment was changed to pulses 
of methylprednisolone (500 mg for 3 days, follo-
wed by 1 mg/kg/day) and three weekly doses of 
rituximab (375 mg/m2) resulting in blood B-cell 
depletion and disappearance of anti-PR3 antibo-
dies. A few weeks later palatal holes diminished 
in size (Fig. 1B) and all bronchial perforations 
disappeared, covered by fibrous tissue (Fig. 2B). In 
the fourth month after rituximab administration, 
scarring and substantial obstruction of the right 
main bronchus developed with atelectasis of the 
upper and middle lobes of the right lung. The 
patient was transferred to the thoracic surgery 
department, where the right main bronchus was 
re-opened using bronchoscopy. The procedure 
was complicated by bilateral pneumothorax. On 
the seventh day after the procedure fatal pulmo-
nary bleeding developed and the patient died.
Discussion
GPA is a rare disease with an annual inciden-
ce ranging from 0.5 to 10 cases per million people 
[6, 9]. This form of vasculitis usually manifests in 
Figure 1. Hard palate holes; A — before rituximab, B — seven weeks after rituximab regimen
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the fourth and fifth decades of life, with a male:-
female ratio ranging from 1:1 to 1.6:1 [3, 10–14]. 
The course of GPA is variable – from slow to rapid 
progression leading to life-threatening multiorgan 
failure, which invariably leads to death [15]. 
Conventional induction treatment comprises 
cyclophosphamide combined with glucocortico-
ids [7]. Unresponsive cases have recently been 
treated by rituximab [15]. Rituximab, an anti-
-CD20 monoclonal antibody developed to treat 
B-cell malignancies, has also been used recently 
in the treatment of several autoimmune diseases 
[15–17]. It leads to a rapid depletion of CD20 
cells from the circulating blood paralleled by 
a significant decrease in disease activity observed 
in the first 6 months in up to 88% of patients 
[3, 7, 16–21]. We used rituximab in our patient 
because of GPA progression despite conventional 
cyclophosphamide treatment. It manifested with 
three large hard palate perforations and multiple 
perforations in the trachea and bronchi. Only 
a few cases of GPA with palate perforations were 
reported, and most of these patients were treated 
with glucocorticoids and cyclophosphamide with 
temporary benefits [22, 23]. To the best of our 
knowledge, nobody has previously described GPA 
with palate perforations associated with trache-
al and bronchial perforations, which appeared 
during standard cyclophosphamide i.v. therapy. 
Beneficial effects of rituximab in our patient (par-
tial or complete healing) were associated with the 
disappearance of ANCA from peripheral blood. 
Preferred regimen of rituximab administration 
in GPA includes four (500 mg) or two (1000 mg) 
weekly doses, leading to disease remission in the 
majority of patients [17]. Maximal effectiveness 
of rituximab is often observed when anti-CD20 
antibody is administered in combination with 
glucocorticoids [15]. Rituximab B-cells return to 
peripheral blood 9–12 months after infusion [18]. 
For this reason, in GPA some physicians suggest 
additional doses of rituximab every six months 
[17]. Rituximab is very well tolerated; major in-
fections during the B-cell depletion treatment are 
uncommon [16]. General experience in treating of 
GPA patients with respiratory tract perforations 
is very limited [22, 23]. However, it seems that 
rituximab might be an option in such patients, 
especially if they are unresponsive to cyclopho-
sphamide.
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